Yaşar Nagihan G, Yiğman Zeynep, Billur Deniz, Tufan Abdurrahman, Gündüz Bülent, Kamişli Gurbet I Ş, Karamert Recep
Department of Otolaryngology-Head and Neck Surgery, Ankara City Hospital, Ankara, Turkey.
Department of Histology and Embryology, Gazi University Faculty of Medicine, Ankara, Turkey.
Otolaryngol Head Neck Surg. 2025 Apr;172(4):1364-1373. doi: 10.1002/ohn.1101. Epub 2024 Dec 22.
This study aimed to attenuate cochlear inflammation following noise-induced hearing loss by targeting IL-1. We evaluated the effectiveness of IL-1 inhibition through auditory and histological assessments in an animal model.
Experimental animal study.
Gazi University Faculty of Medicine, Ankara, Turkey.
Twenty-four rats were randomly assigned into 3 groups: Anakinra, dexamethasone, and control groups. All animals were exposed to broadband noise (110 dB SPL, 8 hours), auditory brainstem response (ABR) tests were conducted before noise exposure, immediately after, and on Day 14. Anakinra, dexamethasone, and saline were administered intraperitoneally, cochlear tissues were harvested for histological and immunohistochemical evaluation.
On Day 14, ABR thresholds in Anakinra group were better than the control group across all frequencies, with a significant difference observed at 8 kHz (P = .036). The mean number of OHC was significantly higher in Anakinra group compared to the control group (P < .05). The mean number of IHC in the Anakinra group was greater than in the dexamethasone group. IL-1β immunopositivity in the stria vascularis and spiral ganglia was significantly higher in Anakinra group compared to dexamethasone group (P = .022 and P = .013, respectively). TNF-α immunopositivity in the stria vascularis and spiral ganglia was significantly greater in control group than in Anakinra group (P = .037 and P = .01, respectively).
The comparable efficacy of Anakinra and dexamethasone in both histological and auditory assessments suggests that Anakinra may serve as a promising therapeutic option for noise-induced hearing loss.
本研究旨在通过靶向白细胞介素-1(IL-1)减轻噪声性听力损失后的耳蜗炎症。我们在动物模型中通过听觉和组织学评估来评价抑制IL-1的效果。
实验性动物研究。
土耳其安卡拉加齐大学医学院。
将24只大鼠随机分为3组:阿那白滞素组、地塞米松组和对照组。所有动物均暴露于宽带噪声(110 dB SPL,8小时),在噪声暴露前、暴露后即刻及第14天进行听性脑干反应(ABR)测试。腹腔注射阿那白滞素、地塞米松和生理盐水,采集耳蜗组织进行组织学和免疫组化评估。
在第14天,阿那白滞素组在所有频率下的ABR阈值均优于对照组,在8 kHz时差异有统计学意义(P = 0.036)。与对照组相比,阿那白滞素组外毛细胞(OHC)的平均数量显著更高(P < 0.05)。阿那白滞素组内毛细胞(IHC)的平均数量多于地塞米松组。与地塞米松组相比,阿那白滞素组血管纹和螺旋神经节中IL-1β免疫阳性率显著更高(分别为P = 0.022和P = 0.013)。与阿那白滞素组相比,对照组血管纹和螺旋神经节中肿瘤坏死因子-α(TNF-α)免疫阳性率显著更高(分别为P = 0.037和P = 0.01)。
阿那白滞素和地塞米松在组织学和听觉评估方面具有相当的疗效,这表明阿那白滞素可能是治疗噪声性听力损失的一种有前景的治疗选择。